Cancer as well as cardiovascular, neurodegenerative, infectious and autoimmune diseases impose a heavy burden on mankind. The Center for Translational Molecular Medicine (CTMM) strives to significantly reduce the impact of these diseases and improve the quality of life for those who must live with them.
CTMM is dedicated to the development of Molecular Diagnostics and Molecular Imaging technologies, focusing firmly on the translational aspects of molecular medicine so that scientific results can be applied as quickly as possible in actual patient care. Achieving this objective could enable earlier and more precise diagnosis of disease and the design of highly personalized therapies.
All Dutch university medical centers, several universities and more than 90 companies are involved, actively cooperating with one another to bring new products faster to the patient’s bedside. Currently, 32 CTMM research projects are active, involving a total of 133 partners and a research budget of 321 M€. Duration of the projects is 4 – 5 years, ending in 2015. The so-called research pearls will continue until end of 2017. Primary funding is provided by the Dutch government (50%), industry (25%) and academia (25%), with additional funding contributed by CTMM supporting foundations (Dutch Diabetes Foundation, Dutch Kidney Foundation, Dutch Arthritis Foundation, Dutch Cancer Society, Dutch Digestive Foundation and the Dutch Heart Foundation).
A typical CTMM project example is the BioCHIP project, in which the AMLProfiler was developed. AMLProfiler is a comprehensive diagnostic test for Acute Myeloid Leukemia (AML), a device of the SME partner Skyline Diagnostics in Rotterdam, that simultaneously analyses several different diagnostic and prognostic markers on the same microarray. Combined with its underlying IT infrastructure, the AMLProfiler can lead to standardized cost-effective laboratory workflows that enable physicians to make precise diagnoses of AML subtype within four days. This helps clinicians to choose the most appropriate available treatment for each patient and perhaps more importantly, create valuable time to search a donor for a matching bone marrow transplant, resulting in better patient outcomes.
The AMLProfiler was launched in Europe as a diagnostic service in December 2009 and is offered as an in-vitro diagnostic (IVD) test. In the USA, CTMM partner Skyline was the first company to apply for FDA Pre-Market Approval (PMA) for a diagnostic microarray.
In the video documentary underneath you will see three of the 65 CTMM SME partners with breaking news:
- A demonstration of the above mentioned AMLProfiler by Thomas Dijkmans of Skyline Diagnostics BV.
- A diagnostic tool for patients with diabetes type 2, measuring the glycocalyx layer in microvessels under the tongue. Interview with Pieter Goedhart from GlycoCheck BV, being a spin-off company of the CTMM PREDICCt project
- How doctors can see via 3D images on how they can best perform an operation, from which side they want to approach a body and how blood vessels structure is. Demonstration by Jackie Schooleman, founder of Virtual Proteins BV, one of the partners in the CTMM LeARN project.
Key figures of CTMM:
Above-mentioned statistics come from CTMM book Translating Science into Better Healthcare, page 50.
As of January 1st, 2016, CTMM and TI Pharma merged into the new organization Lygature.